gb PHARM CYP2C19

• kit requires manual preparation of reagents and samples, which are then analysed with the use of real-time PCR cycler instrument
• intended for testing in Caucasian population
• intended for laboratory professional use by trained healthcare professionals
• detection of CYP2C19*2, CYP2C19*3 and CYP2C19*17 polymorphisms serves as an aid to determine slow, normal or rapid metabolizers among patients using pharmaceuticals from the range of antidepressants, anticoagulants and antifungal agents

Clinical implications

CYP2C19 is a clinically relevant enzyme involved in the biotransformation of a range of antidepressant, anticoagulant and antimycotic drugs. Side effects of clopidogrel treatment are associated with severe consequences. Clopidogrel is a very effective antiplatelet drug, the effect of which is based on an irreversible inhibition of platelet receptor P2RY12. It is a pro-drug that is activated by the cytochrome P450 complex, predominantly by the CYP2C19. Slow metabolizers are the most common carriers of the allele *2 and *3 and ultra-fast metabolism is associated with the allele *17 in the Caucasian population. Slow metabolisers do not produce an active form of the drug and they are in risk of non functional treatment. The ultra-fast metabolisers are in danger of bleeding conditions due to reduced platelet activity.